Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2016 2
2017 1
2018 1
2019 2
2020 3
2021 3
2022 5
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial.
Seiler R, Egger M, De Menna M, Wehrli S, Minoli M, Radić M, Lyatoshinsky P, Hösli R, Blarer J, Abt D, Kruithof-de Julio M. Seiler R, et al. Among authors: de menna m. BMC Urol. 2023 May 11;23(1):89. doi: 10.1186/s12894-023-01262-1. BMC Urol. 2023. PMID: 37170307 Free PMC article. Clinical Trial.
A model for network-based identification and pharmacological targeting of aberrant, replication-permissive transcriptional programs induced by viral infection.
Laise P, Stanifer ML, Bosker G, Sun X, Triana S, Doldan P, La Manna F, De Menna M, Realubit RB, Pampou S, Karan C, Alexandrov T, Kruithof-de Julio M, Califano A, Boulant S, Alvarez MJ. Laise P, et al. Among authors: de menna m. Commun Biol. 2022 Jul 19;5(1):714. doi: 10.1038/s42003-022-03663-8. Commun Biol. 2022. PMID: 35854100 Free PMC article.
Author Correction: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.
Bianco G, Coto-Llerena M, Gallon J, Kancherla V, Taha-Mehlitz S, Marinucci M, Konantz M, Srivatsa S, Montazeri H, Panebianco F, Tirunagaru VG, De Menna M, Paradiso V, Ercan C, Dahmani A, Montaudon E, Beerenwinkel N, Kruithof-de Julio M, Terracciano LM, Lengerke C, Jeselsohn RM, Doebele RC, Bidard FC, Marangoni E, Ng CKY, Piscuoglio S. Bianco G, et al. Among authors: de menna m. Commun Biol. 2022 Jul 4;5(1):658. doi: 10.1038/s42003-022-03612-5. Commun Biol. 2022. PMID: 35787660 Free PMC article. No abstract available.
GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.
Bianco G, Coto-Llerena M, Gallon J, Kancherla V, Taha-Mehlitz S, Marinucci M, Konantz M, Srivatsa S, Montazeri H, Panebianco F, Tirunagaru VG, De Menna M, Paradiso V, Ercan C, Dahmani A, Montaudon E, Beerenwinkel N, Kruithof-de Julio M, Terracciano LM, Lengerke C, Jeselsohn RM, Doebele RC, Bidard FC, Marangoni E, Ng CKY, Piscuoglio S. Bianco G, et al. Among authors: de menna m. Commun Biol. 2022 Apr 19;5(1):373. doi: 10.1038/s42003-022-03296-x. Commun Biol. 2022. PMID: 35440675 Free PMC article.
Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment.
Hirt CK, Booij TH, Grob L, Simmler P, Toussaint NC, Keller D, Taube D, Ludwig V, Goryachkin A, Pauli C, Lenggenhager D, Stekhoven DJ, Stirnimann CU, Endhardt K, Ringnalda F, Villiger L, Siebenhüner A, Karkampouna S, De Menna M, Beshay J, Klett H, Kruithof-de Julio M, Schüler J, Schwank G. Hirt CK, et al. Among authors: de menna m. Cell Genom. 2022 Feb;2(2):100095. doi: 10.1016/j.xgen.2022.100095. Cell Genom. 2022. PMID: 35187519 Free PMC article.
A Model for Network-Based Identification and Pharmacological Targeting of Aberrant, Replication-Permissive Transcriptional Programs Induced by Viral Infection.
Laise P, Stanifer ML, Bosker G, Sun X, Triana S, Doldan P, La Manna F, De Menna M, Realubit RB, Pampou S, Karan C, Alexandrov T, Kruithof-de Julio M, Califano A, Boulant S, Alvarez MJ. Laise P, et al. Among authors: de menna m. Res Sq [Preprint]. 2022 Feb 4:rs.3.rs-1287631. doi: 10.21203/rs.3.rs-1287631/v1. Res Sq. 2022. PMID: 35132404 Free PMC article. Updated. Preprint.
Corrigendum: Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity.
La Manna F, De Menna M, Patel N, Karkampouna S, De Filippo MR, Klima I, Kloen P, Beimers L, Thalmann GN, Pelger RCM, Jacinto E, Kruithof-de Julio M. La Manna F, et al. Among authors: de menna m. Front Oncol. 2021 Feb 3;11:650623. doi: 10.3389/fonc.2021.650623. eCollection 2021. Front Oncol. 2021. PMID: 33614519 Free PMC article.
Patient-derived xenografts and organoids model therapy response in prostate cancer.
Karkampouna S, La Manna F, Benjak A, Kiener M, De Menna M, Zoni E, Grosjean J, Klima I, Garofoli A, Bolis M, Vallerga A, Theurillat JP, De Filippo MR, Genitsch V, Keller D, Booij TH, Stirnimann CU, Eng K, Sboner A, Ng CKY, Piscuoglio S, Gray PC, Spahn M, Rubin MA, Thalmann GN, Kruithof-de Julio M. Karkampouna S, et al. Among authors: de menna m. Nat Commun. 2021 Feb 18;12(1):1117. doi: 10.1038/s41467-021-21300-6. Nat Commun. 2021. PMID: 33602919 Free PMC article.
17 results